Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Centre Hospitalier Departemental Vendee
The primary objective is to determine whether early evolution (between baseline and week 3) of circulating tumor DNA concentration predicts the radiological response to first-line treatment of advanced or metastatic NSCLC patients, regardless of treatment
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Metastatic or locally advanced non-small cell lung cancer (stage III or IV)
At least one measurable target according to RECIST criteria
Identification of at least one molecular alteration in the tissue sample analyzed in the framework of patient management
Performance Status 0 to 2
Affiliated to a social security system
Patient who can be followed under the protocol
Patient agreed to participate in the study and gave his/her express consent
You may not be if
Minor
Small cell or mixed bronchial cancer
Radiotherapy (except radiotherapy for antalgic purposes) during the last 7 days
Patient who has already started a first line of treatment
Patient already included in an interventional research protocol that may have an impact on the results of the ELUCID study
History of cancer (with the exception of non-melanoma skin, cervical cancer in situ, adequately treated) with sign of illness during the last 5 years
Patient which, does present a substantial risk of recurrence.
Major under guardianship, curators or deprived of liberty
Pregnant or lactating woman, or of childbearing age without effective contraception
Not affiliated to a social security system
Inability to understand the protocol and / or to give express consent